Sunday , 19 May 2024

Formulation Development and In-vitro Characterization of Scopolamine Transdermal Patches

J. Praveen Kumar*1, E. Vijay Kumar2, K.Madan3, G.Maheswar4, A. Madhu Bindu5
*1KLR Pharmacy College, Palvancha, Telangana, India

2Srinivasa Institute of Pharmaceutical Sciences, Proddatur, Andhra Pradesh, India
3KLR Pharmacy College, Palvancha, Telangana, India
4Srinivasa Institute of Pharmaceutical Sciences, Proddatur, Andhra Pradesh, India
5PRRM College of Pharmacy, Kadapa, Andhra Pradesh, India

In present study transdermal drug delivery of Scopolamine   was developed to overcome the first pass metabolism and to reduce frequency of dosing compared to oral route. Oral drug delivery system has various drawbacks like poor bioavailability due to hepatic metabolism (first pass) and the tendency to produce rapid blood level spikes (both high and low), leading to a need for high and/or frequent dosing, which can be both cost prohibitive and inconvenient. Matrix type of transdermal patches was developed by using polymers Eudragit polymers Transdermal patches were prepared by employing solvent casting method. Drug excipient compatibility studies were carried out by using FT-IR, and it was observed that there were no interactions. Formulations were prepared with the varying concentrations polymers ranging from F1-F9, and all the formulations were evaluated for various physical parameters Physical appearance, Flatness, Weight variation, Thickness, Folding endurance, Drug content, Moisture uptake, Moisture content and Swelling study and all the results were found to be were found to be with in the pharmacopeial limits, invitro drug release studies by using dialysis membrane. Among all the 12 formulations F9 formulation which contain Eudragit S-100 and Eudragit L-100 200mg each  had shown 99.6% cumulative drug release with in 8 hours.

Keywords: Scopolamine, Transdermal patches, Eudragit S-100 ,Eudragit L-100

Scroll To Top